Tolvaptan
Payments companies reported to CMS as associated with Tolvaptan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tolvaptan, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tolvaptan
These are the largest totals companies reported as associated with Tolvaptan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Linda Cappiello-Lindsley | Hoboken, NJ | Dermatology | $320,443.20 |
| David Alpers | Saint Louis, MO | Gastroenterology (Internal Medicine) | $43,500.00 |
| James Freston | Farmington, CT | Gastroenterology (Internal Medicine) | $25,100.00 |
| James Lewis | Washington, DC | Gastroenterology (Internal Medicine) | $24,292.00 |
| Christine Hunt | Chapel Hill, NC | Gastroenterology (Internal Medicine) | $23,028.00 |
| Fouad Chebib | Jacksonville, FL | Nephrology (Internal Medicine) | $19,690.29 |
| Ronald Perrone | Boston, MA | Nephrology (Internal Medicine) | $18,636.32 |
| Michael Lioudis | Camillus, NY | Nephrology (Internal Medicine) | $16,060.75 |
| Laurence Greenbaum | Atlanta, GA | Pediatric Nephrology | $15,358.50 |
| Meyeon Park | San Francisco, CA | Nephrology (Internal Medicine) | $14,822.16 |
Prescribed Tolvaptan?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.